[go: up one dir, main page]

WO2012138955A3 - Acides nucléiques gamma-peptidiques contenant du minipeg, conformationnellement préorganisés - Google Patents

Acides nucléiques gamma-peptidiques contenant du minipeg, conformationnellement préorganisés Download PDF

Info

Publication number
WO2012138955A3
WO2012138955A3 PCT/US2012/032459 US2012032459W WO2012138955A3 WO 2012138955 A3 WO2012138955 A3 WO 2012138955A3 US 2012032459 W US2012032459 W US 2012032459W WO 2012138955 A3 WO2012138955 A3 WO 2012138955A3
Authority
WO
WIPO (PCT)
Prior art keywords
minipeg
preorganized
conformationally
nucleic acids
peptide nucleic
Prior art date
Application number
PCT/US2012/032459
Other languages
English (en)
Other versions
WO2012138955A2 (fr
Inventor
Danith H. Ly
Srinivas RAPIREDDY
Bichismita Sahu
Original Assignee
Ly Danith H
Rapireddy Srinivas
Bichismita Sahu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2832553A priority Critical patent/CA2832553A1/fr
Application filed by Ly Danith H, Rapireddy Srinivas, Bichismita Sahu filed Critical Ly Danith H
Priority to ES12767656T priority patent/ES2745504T3/es
Priority to EP21164008.1A priority patent/EP3913065A1/fr
Priority to EP12767656.7A priority patent/EP2694683B1/fr
Priority to EP18187994.1A priority patent/EP3428287B1/fr
Priority to US14/110,689 priority patent/US9193758B2/en
Publication of WO2012138955A2 publication Critical patent/WO2012138955A2/fr
Publication of WO2012138955A3 publication Critical patent/WO2012138955A3/fr
Priority to US14/921,755 priority patent/US10093700B2/en
Priority to US15/972,494 priority patent/US10160787B2/en
Priority to US16/145,075 priority patent/US10364272B2/en
Priority to US16/362,579 priority patent/US10793605B2/en
Priority to US17/003,131 priority patent/US11279736B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des monomères γ-ΡΝΑ selon la Formule I où les groupes de substitution R1, R2, R3, R4, R5, R6, B et P sont définis comme énoncé dans la description. L'invention concerne également une méthodologie pour la synthèse de composés selon la Formule I et une méthodologie pour la synthèse d'oligomères de PNA qui incorporent un ou plusieurs monomères de Formule I.
PCT/US2012/032459 2011-04-08 2012-04-06 Acides nucléiques gamma-peptidiques contenant du minipeg, conformationnellement préorganisés WO2012138955A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US14/110,689 US9193758B2 (en) 2011-04-08 2012-04-06 Conformationally-preorganized, miniPEG-containing γ-peptide nucleic acids
ES12767656T ES2745504T3 (es) 2011-04-08 2012-04-06 Acidos nucleicos peptídicos gamma que contienen miniPEG preorganizados conformacionalmente
EP21164008.1A EP3913065A1 (fr) 2011-04-08 2012-04-06 Acides nucléiques gamma-peptidiques contenant du minipeg conformationnellement préorganisés
EP12767656.7A EP2694683B1 (fr) 2011-04-08 2012-04-06 ACIDES NUCLÉIQUES GAMMA-PEPTIDIQUES CONTENANT DU MiniPEG, CONFORMATIONNELLEMENT PRÉORGANISÉS
EP18187994.1A EP3428287B1 (fr) 2011-04-08 2012-04-06 Acides nucléiques gamma-peptidiques contenant du minipeg conformationnellement préorganisés
CA2832553A CA2832553A1 (fr) 2011-04-08 2012-04-06 Acides nucleiques gamma-peptidiques contenant du minipeg, conformationnellement preorganises
US14/921,755 US10093700B2 (en) 2011-04-08 2015-10-23 Conformationally-preorganized, MiniPEG-containing gamma-peptide nucleic acids
US15/972,494 US10160787B2 (en) 2011-04-08 2018-05-07 Conformationally-preorganized, miniPEG-containing gamma-peptide nucleic acids
US16/145,075 US10364272B2 (en) 2011-04-08 2018-09-27 Conformationally-preorganized, miniPEG-containing gamma-peptide nucleic acids
US16/362,579 US10793605B2 (en) 2011-04-08 2019-03-22 Conformationally-preorganized, miniPEG-containing γ-peptide nucleic acids
US17/003,131 US11279736B2 (en) 2011-04-08 2020-08-26 Conformationally-preorganized, MiniPEG-containing gamma-peptide nucleic acids

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161516812P 2011-04-08 2011-04-08
US201161516838P 2011-04-08 2011-04-08
US61/516,838 2011-04-08
US61/516,812 2011-04-08

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US14/110,689 A-371-Of-International US9193758B2 (en) 2011-04-08 2012-04-06 Conformationally-preorganized, miniPEG-containing γ-peptide nucleic acids
US14/921,755 Continuation US10093700B2 (en) 2011-04-08 2015-10-23 Conformationally-preorganized, MiniPEG-containing gamma-peptide nucleic acids
US14/921,755 Division US10093700B2 (en) 2011-04-08 2015-10-23 Conformationally-preorganized, MiniPEG-containing gamma-peptide nucleic acids

Publications (2)

Publication Number Publication Date
WO2012138955A2 WO2012138955A2 (fr) 2012-10-11
WO2012138955A3 true WO2012138955A3 (fr) 2013-01-24

Family

ID=46969830

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/032459 WO2012138955A2 (fr) 2011-04-08 2012-04-06 Acides nucléiques gamma-peptidiques contenant du minipeg, conformationnellement préorganisés

Country Status (5)

Country Link
US (6) US9193758B2 (fr)
EP (3) EP3428287B1 (fr)
CA (1) CA2832553A1 (fr)
ES (1) ES2745504T3 (fr)
WO (1) WO2012138955A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11859242B2 (en) 2017-12-21 2024-01-02 Carnegie Mellon University Template-directed nucleic acid targeting compounds

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2745504T3 (es) 2011-04-08 2020-03-02 Univ Carnegie Mellon Acidos nucleicos peptídicos gamma que contienen miniPEG preorganizados conformacionalmente
WO2013074601A1 (fr) 2011-11-14 2013-05-23 Carnegie Mellon University Center For Technology Transfer & Enterprise Minisondes gamma-pna pour un marquage fluorescent
US9663830B2 (en) 2012-05-20 2017-05-30 Helixbind Methods and compositions for the diagnosis of sepsis using gamma peptide nucleic acids
WO2014169216A2 (fr) * 2013-04-11 2014-10-16 Carnegie Mellon University Synthèse de γpna dirigée par une matrice et composés ciblant γpna
US10370415B2 (en) 2013-04-11 2019-08-06 Carnegie Mellon University Divalent nucleobase compounds and uses therefor
WO2015172058A1 (fr) * 2014-05-08 2015-11-12 Carnegie Mellon University Acides nucléiques gamma-peptidiques à hélice à pas de rotation à gauche, leurs procédés de synthèse et utilisations
EP3350343B1 (fr) * 2015-09-16 2020-04-22 Petaomics, Inc. Procédés et compositions pour l'enrichissement d'une cible génomique et le séquençage sélectif d'adn
CA3014792A1 (fr) 2016-02-16 2017-08-24 Carnegie Mellon University Compositions permettant d'ameliorer l'edition ciblee de genes et leurs procedes d'utilisation
EP3523284A4 (fr) 2016-09-26 2021-07-07 Carnegie Mellon University Composés de nucléobase divalent et leurs utilisations
CN110832085A (zh) 2017-04-03 2020-02-21 海利克斯拜恩德股份有限公司 用于鉴定微生物感染的方法和装置
WO2018187493A1 (fr) 2017-04-04 2018-10-11 Yale University Compositions et procédés d'administration in utero
CA3070058A1 (fr) * 2017-07-17 2019-01-24 Trucode Gene Repair, Inc. Monomeres d'acide nucleique peptidique (pna) avec une fraction ester a protection orthogonale, nouveaux intermediaires et procedes associes
CN111491667A (zh) 2017-12-18 2020-08-04 文塔纳医疗系统公司 肽核酸缀合物
EP3727435A4 (fr) * 2017-12-21 2021-09-08 Carnegie Mellon University Ligands bivalents d'acides nucléiques et leurs utilisations
US20210189431A1 (en) 2018-08-10 2021-06-24 Yale University Compositions and methods for embryonic gene editing in vitro
WO2020047353A1 (fr) 2018-08-31 2020-03-05 Yale University Compositions et procédés pour améliorer l'édition de gènes à base de triplex et de nucléase
WO2020112195A1 (fr) 2018-11-30 2020-06-04 Yale University Compositions, technologies et procédés d'utilisation de plérixafor pour améliorer l'édition de gènes
US12297231B2 (en) 2019-03-29 2025-05-13 Carnegie Mellon University Shape-responsive nanostructures
CA3137012A1 (fr) 2019-04-16 2020-10-22 Helixbind, Inc. Methodes et dispositifs pour la detection ultrasensible directe de micro-organismes
WO2020219819A1 (fr) * 2019-04-24 2020-10-29 University Of South Florida INTERACTION PROTÉINE-PROTÉINE DE β−CATÉNINE/LYMPHOME 9 À CELLULES B INHIBANT DES PEPTIDOMIMÉTIQUES
US20220243211A1 (en) * 2019-06-21 2022-08-04 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
US20220372474A1 (en) 2019-06-21 2022-11-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
US20220339294A1 (en) 2019-09-09 2022-10-27 Yale University Nanoparticles for selective tissue or cellular uptake
WO2021133032A1 (fr) * 2019-12-24 2021-07-01 주식회사 시선바이오머티리얼스 Composé à squelette à carbone en position gamma modifié et son procédé de préparation
US11833254B2 (en) 2020-05-27 2023-12-05 University Of Connecticut Discoidal nano universal platform for efficient delivery of PNAs
US20240190924A1 (en) * 2021-03-01 2024-06-13 Carnegie Mellon University Synthesis of Gamma Peptide Nucleic Acid Monomers and Oligomers, and Applications Therefor

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063569A (en) * 1995-06-07 2000-05-16 Perseptive Biosystems, Inc. Methods for automated synthesis of PNA-DNA chimeras and compositions thereof
US6121418A (en) * 1994-03-14 2000-09-19 Hoechst Aktiengesellschaft PNA synthesis using a base-labile amino protecting group
US6169169B1 (en) * 1994-05-19 2001-01-02 Dako A/S PNA probes for detection of Neisseria gonorrhoeae and Chlamydia trachomatis
WO2004024757A2 (fr) * 2002-09-11 2004-03-25 Santaris Pharma A/S Molecules pna modifiées
US20050009041A1 (en) * 1991-05-24 2005-01-13 Ole Buchardt Peptide nucleic acids and synthetic procedures therefor
US20060159619A1 (en) * 2004-10-15 2006-07-20 Becker Matthew L Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids ("PNAs") with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK51092D0 (da) 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US7223833B1 (en) 1991-05-24 2007-05-29 Isis Pharmaceuticals, Inc. Peptide nucleic acid conjugates
US6107470A (en) 1997-05-29 2000-08-22 Nielsen; Peter E. Histidine-containing peptide nucleic acids
US6632922B1 (en) * 1998-03-19 2003-10-14 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US20030207804A1 (en) 2001-05-25 2003-11-06 Muthiah Manoharan Modified peptide nucleic acids
ES2745504T3 (es) 2011-04-08 2020-03-02 Univ Carnegie Mellon Acidos nucleicos peptídicos gamma que contienen miniPEG preorganizados conformacionalmente

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050009041A1 (en) * 1991-05-24 2005-01-13 Ole Buchardt Peptide nucleic acids and synthetic procedures therefor
US6121418A (en) * 1994-03-14 2000-09-19 Hoechst Aktiengesellschaft PNA synthesis using a base-labile amino protecting group
US6169169B1 (en) * 1994-05-19 2001-01-02 Dako A/S PNA probes for detection of Neisseria gonorrhoeae and Chlamydia trachomatis
US6063569A (en) * 1995-06-07 2000-05-16 Perseptive Biosystems, Inc. Methods for automated synthesis of PNA-DNA chimeras and compositions thereof
WO2004024757A2 (fr) * 2002-09-11 2004-03-25 Santaris Pharma A/S Molecules pna modifiées
US20060159619A1 (en) * 2004-10-15 2006-07-20 Becker Matthew L Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids ("PNAs") with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11859242B2 (en) 2017-12-21 2024-01-02 Carnegie Mellon University Template-directed nucleic acid targeting compounds

Also Published As

Publication number Publication date
US20190062378A1 (en) 2019-02-28
US10364272B2 (en) 2019-07-30
US10793605B2 (en) 2020-10-06
US9193758B2 (en) 2015-11-24
US20190292227A1 (en) 2019-09-26
US20210214397A1 (en) 2021-07-15
EP2694683A2 (fr) 2014-02-12
US10093700B2 (en) 2018-10-09
ES2745504T3 (es) 2020-03-02
EP2694683A4 (fr) 2014-12-17
EP3913065A1 (fr) 2021-11-24
US20180291065A1 (en) 2018-10-11
US11279736B2 (en) 2022-03-22
US20140128570A1 (en) 2014-05-08
CA2832553A1 (fr) 2012-10-11
EP3428287A1 (fr) 2019-01-16
EP3428287B1 (fr) 2021-03-24
US10160787B2 (en) 2018-12-25
US20160096867A1 (en) 2016-04-07
WO2012138955A2 (fr) 2012-10-11
EP2694683B1 (fr) 2019-08-28

Similar Documents

Publication Publication Date Title
WO2012138955A3 (fr) Acides nucléiques gamma-peptidiques contenant du minipeg, conformationnellement préorganisés
WO2013162715A3 (fr) Compositions pesticides et procédés correspondants
WO2010151797A3 (fr) Composés de modulation des protéines de liaison à l'arn et applications associées
EP4410805A3 (fr) Compositions à base de raav et procédés pour traiter la sclérose latérale amyotrophique
WO2009100320A3 (fr) Analogues d’acides nucléiques de cyclohexitol bicycliques
WO2010018563A3 (fr) Compositions et procédés de pronostic d'un lymphome
WO2012061290A3 (fr) Compositions pesticides et procédés associés
WO2010063700A8 (fr) Nouveaux microbiocides
MX315135B (en) 2, 6-diamino- pyrimidin- 5-yl-carboxamides as SYK or JAK kinases inhibitors
WO2012135025A3 (fr) Lipomères conjugués et utilisations associées
IL208638A0 (en) 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
WO2009043889A3 (fr) Dérivés d'oxadiazole
WO2010068292A8 (fr) Dérivés d'azaindole en tant qu'inhibiteurs de kinases
MX353308B (es) Derivados fosforosos como inhibidores de cinasa.
CA2830549C (fr) Procedes et compositions pour la preparation de noribogaine a partir de voacangine
WO2008128072A3 (fr) Inhibiteurs de la kinase axl
WO2013067349A9 (fr) Nouvelle chimie utilisée dans des biocapteurs
WO2009079008A8 (fr) Benzopyranes et analogues utilisés comme inhibiteurs de la rho kinase
WO2007133560A3 (fr) Composés d'hétéroaryle acétylénique
MX2013009252A (es) Composiciones y procesos relacionados con los mismos plaguicidas.
WO2012054664A3 (fr) Compositions d'encres
WO2007133562A3 (fr) Composés d'hétéroaryle monocyclique
FR2994849B1 (fr) Formulation pour la delivrance de sequences nucleotidiques susceptibles de moduler des mecanismes endogenes d'arn interferents
WO2011132051A3 (fr) Composés tricycliques en tant qu'inhibiteurs de la phosphodiestérase-10
WO2009127718A3 (fr) Nouveaux microbiocides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12767656

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2832553

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012767656

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 14110689

Country of ref document: US